EHMSG 2021 Virtual Conference | e-Poster Presentations

Electronic Poster Round 1: Diagnosis of Helicobacter infection

P01.01
Prevalence of clarithromycin resistant strains in Helicobacter pylori positive patients after COVID-19
Presenting Author: Valeriy Kryvy, Simferopol, Russian Federation

P01.02
New rapid H.pylori blood test based on FLID and Cag A antibodies detection
Presenting Author: Christian Schulz, Munich, Germany

P01.03
The frequency of false positive Helicobacter urease tests during the routine endoscopy is negligible low
Presenting Author: Alexander Link, Magdeburg, Germany

P01.04
Comparative evaluation of Helicobacter pylori susceptibility testing methods to optimize routine analysis.
Presenting Author: Véronique MIENDJE DEYI, Brussels, Belgium

P01.05
H. pylori diagnostic tests used in naïve patients: Results from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Ignasi Puig, Manresa, Spain

P01.06
The patient experience and clinical efficacy of a novel virtual C13UBT service at an Irish tertiary referral center during the Covid 19 pandemic.
Presenting Author: Sandeep Sihag, Dublin, Ireland

P01.07
Molecular diagnosis of Helicobacter pylori: validation of Allplex™ H. pylori and ClariR Assay
Presenting Author: Pierre Bogaerts, Yvoir, Belgium

P01.08
Comparison of histological examination and semi-quantitative detection of H. pylori infection: a pilot study.
Presenting Author: Elena Kolomina, St. Petersburg, Russian Federation

​

P01.09
Helicobacter pylori infection -related metabolic and gastric mucosa pre-malignant histological parameters in Swiss bariatric patients
Presenting Author: Michael Doulberis, Gastroenterology, Switzerland

​

P01.10
The prevalence of Helicobacter pylori infection among dyspeptic patients in Northwestern Romania: a decreasing epidemiological trend in the last 30 years
Presenting Author: Alexandra Corojan, Cluj-Napoca, Romania

​

P01.11
Molecular diagnosis and histopathology: is there a difference between the methods for detecting Helicobacter pylori in severe and non-severe esogastroduodenal lesions?
Presenting Author: Mônica Barbosa, Goiânia, Brazil

​

P01.12
Two types of ammonium breath test for detection of H. pylori infection
Presenting Author: Natalia Baryshnikova, St-Petersburg, Russian Federation

​

P01.13
Accuracy of gastric biopsy-based methods for diagnosis of Helicobacter pylori infection in symptomatic Vietnamese children.
Presenting Author: Tu Nguyen Cam, Ho Chi Minh City, Viet Nam

Electronic Poster Round 2: Treatment of Helicobacter infection

P02.01
Efficacy of vonoprazan-based dual therapy and vonoprazan-based triple therapy for Helicobacter pylori eradication: A prospective randomized study
Presenting Author: Sarita Ratana-Amornpin, Pathum Thani, Thailand

​

P02.02
A double-blind, placebo-controlled, multicenter study of the efficacy and safety of alpha-glutamyl-tryptophan in the treatment of chronic atrophic gastritis, associated with H. pylori
Presenting Author: Natalia Baryshnikova, St-Petersburg, Russian Federation

​

P02.03
Tackling Helicobacter pylori infection by a pre-clinical prophylactic vaccination strategy
Presenting Author: Verena Friedrich, Munich, Germany

​

P02.04
A multicenter study on the past use of metronidazole and the success rate of eradication of Helicobacter pylori
Presenting Author: Younghee Choe, Seoul, Korea, Republic of

​

P02.05
Treatments after failed therapy in H. pylori infected children in Europe: Results of the EuroPedHp Registry
Presenting Author: Thu Giang Le Thi, München, Germany

​

P02.06
First-line empirical therapy for the eradication of H. pylori in Italy: data on effectiveness from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

​

P02.07
Second-line empirical therapy for the eradication of H. pylori in Italy: data on effectiveness from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

​

P02.08
Quadruple hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance country: the importance of a close medical-patient relationship
Presenting Author: Catarina Correia, Coimbra, Portugal

​

P02.09
An observational real-life study evaluating the efficacy of 10 and 14-days Concomitant therapy supplemented with probiotics for H pylori eradication in naïve patients in a high Clarithromycin and Metronidazole resistance area
Presenting Author: Kateryna Priadko, Napoli, Italy

​

P02.10
Primary antimicrobial resistance trend in Italian H. pylori naïve patients between 2013-2020: analysis of the European Registry on H. pylori Management (Hp-EuReg
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

​

P02.11
Vonoprazan-based Dual Therapy and High-dose PPI Dual Regimens for H. pylori Eradication: A Comparison of the Available Data
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

​

P02.12
First-line empirical H. pylori eradication therapy in Europe: Results from 30,000 cases of the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

​

P02.13
Empirical first-line treatment use and effectiveness trends in Europe in the period 2013-2020: Results from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

​

P02.14
Empirical second-line treatments in Europe: Results from the European Registry on H. pylori Management (Hp-EuReg
Presenting Author: Olga P. Nyssen, Madrid, Spain

​

P02.15
Experience with single capsule bismuth quadruple therapy in 5,000 patients from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

​

P02.16
Bismuth quadruple three-in-one single capsule: 3 or 4 times daily? Sub-analysis of the Spanish data of the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Ángeles Pérez-Aísa*, Marbella, Spain

​

P02.17
Antibiotic resistance trends of Helicobacter pylori naïve patients in the period 2013-2020: analysis of the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luis Bujanda, San Sebastián, Spain

​

P02.18
Experience with rifabutin-containing therapy in 426 patients from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Olga P. Nyssen, Madrid, Spain

​

P02.19
Non-bismuth quadruple concomitant treatment for H. pylori eradication: systematic review and meta-analysis
Presenting Author: Olga Nyssen, Madrid, Spain

​

P02.20
Eradication of Helicobacter pylori: meta-analysis-based or registry-based? A personal view.
Presenting Author: György Buzás, Budapest, Hungary

​

P02.21
Efficacy and safety of vonoprazan-based quadruple regimens for the eradication of Helicobacter pylori in Chinese patients with peptic ulcer: a pooled analysis of two phase III trials
Presenting Author: Xiaohua Hou, Wuhan, China

​

P02.22
Exploring the potential of bio-active components of Morinda citrifolia and its interaction with the Helicobacter pylori oncogenic protein CagA
Presenting Author: Oindrilla Mukherjee, Durgapur, India

​

P02.23
Gellan Gum hydrogels as a pH-responsive system to control the gastric delivery of highly effective antimicrobial microspheres against Helicobacter pylori
Presenting Author: Diana Fonseca, Porto, Portugal

​

P02.24
Comparative efficacy of eradication triple, sequential therapy and quadruple-therapy in patients after COVID-19
Presenting Author: Valeriy Kryvy, Simferopol, Russian Federation

​

P02.25
Effective eradication regimen and duration according to the results of clarithromycin susceptibility of Helicobacter pylori.
Presenting Author: Byung-Wook Kim, Incheon, Korea, Republic of

​

P02.26
Characteristics of empirical first- and second-line treatment prescribed between 2013-2020:Italian data from the European Registry on H. pylori Management (Hp-EuReg)
Presenting Author: Luigi Gatta, Lido di Camaiore, Italy

​

P02.27
Tuning up nanostructured lipid carriers for specific Helicobacter pylori eradication: effect of size, charge and protein corona
Presenting Author: Rute Chitas, Porto, Portugal

​

P02.28
PPI-amoxicillin dual therapy four times daily is superior to guidelines-recommended regimens in the Helicobacter pylori eradication therapy: a systematic review & meta-analysis
Presenting Author: Cailing Li, Beijing, China

​

P02.29
Comparison of the reading of Clarithromycin E-test on Helicobacter Pylori by eye and with microscope
Presenting Author: Melodi Yusibova, København Ø, Denmark

​

P02.30
Addition of Saccharomyces boulardii to standard triple therapy in eradication of H. pylori: adverse events and compliance
Presenting Author: Olga Sjomina, Riga, Latvia

​

P02.31
Production of biofilm as a feature positively correlated with clarithromycin resistance in Helicobacter pylori
Presenting Author: Paweł Krzyżek, Wrocław, Poland

​

P02.32
Assessment of First-Line Treatment in Greece: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg).
Presenting Author: Theodore Rokkas, Athens, Greece

​

P02.33
Inhibitors of carbonic anhydrases as anti-Helicobacter pylori agents
Presenting Author: Rossella Grande, Chieti, Italy

​

P02.34
Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β
Presenting Author: Natalya Bakulina, Saint Petersburg, Russian Federation

​

P02.35
Development of new synthetic surfactants with anti-Helicobacter effect
Presenting Author: Elena Ermolenko, Saint-Petersburg, Russian Federation

​

P02.36
Evaluation of first-line bismuth containing 7-day quintet therapy for Helicobacter pylori eradication
Presenting Author: Yeji Choi, Seongnam-si, Korea, Republic of

​

P02.37
Adjuvant therapy with eupatilin improves the state of gastric mucosa in patients with H.pylori-associated chronic gastritis and diabetes mellitus type 2
Presenting Author: Igor Skrypnyk, Poltava, Ukraine

​

P02.38
Treatment and diagnosis of Helicobacter infection in Ukraine: successes and mistakes
Presenting Author: Yana Nikiforova, Kharkiv, Ukraine

​

P02.39
Metronidazole susceptibility testing for Helicobacter pylori isolates: comparing agar dilution method & Epsilomete test
Presenting Author: Xueli Tian, Beijing, China

​

P02.40
Comparison of the success rate of eradication of helicobacter pylori between hemodialysis patients and non-hemodialysis patients
Presenting Author: Seung Han Kim, Seoul, Korea, Republic of

​

P02.41
Helicobacter pylori & primary antibiotic resistance in the region of northeastern Romania
Presenting Author: Elena Popovici, Bacau, Romania

Electronic Poster Round 3: Gastric cancer

​

P03.01
Proteomic signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer
Presenting Author: Xue Li, Beijing, China

​

P03.02
Current smoking and H. pylori status is associated with precancerous lesions ,,missed” by serologic pepsinogen testing
Presenting Author: Danute Razuka-Ebela, Riga, Latvia

​

P03.03
Estrogen and Helicobacter pylori CagA may induce stem cell and epithelial mesenchymal transition phenotype in diffuse type gastric adenocarcinomas
Presenting Author: Seungkyung Kang, Seoul, Korea, Republic of

​

P03.04
Leukaemia Inhibitory Factor signalling for targeting Cancer Stem Cells in gastric adenocarcinoma
Presenting Author: Lornella Seeneevassen, Bordeaux, France

​

P03.05
Does microbial lactate play a role in gastric adenocarcinoma?
Presenting Author: Karla Vinasco-Pacheco, Sydney, Australia

​

P03.06
Reprograming of gastric epithelial cells towards precancerogenic and proinvasive phenotype by secretome of Helicobacter pylori-activated fibroblasts
Presenting Author: Tomasz Brzozowski, Cracow, Poland

​

P03.07
Putative impact of CagA protein on DNA damage repair machinery during Helicobacter pylori infection
Presenting Author: Eleftherios Kontizas, Athens, Greece

​

P03.08
Ex-vivo profiling of volatile organic compounds released from gastric cancer and non-cancerous tissue
Presenting Author: Daria Slefarska, Kielce, Poland

​

P03.09
The role of the nonspecific immunity in the progression of gastric cancer associated with Helicobacter pylori infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

​

P03.10
Role of Claudin Proteins for Prediction of Lymphatic or Lymph Node Invasion among Submucosal-Invasive Early Gastric Cancer
Presenting Author: Moon Kyung Joo, Seoul, Korea, Republic of

​

P03.11
Reasons for refusing further endoscopic surveillance in patients with diagnosed precancerous gastric lesions
Presenting Author: Laura Rotberga, Riga, Latvia

​

P03.12
Periodontal disease, gingivitis, periodontitis, tooth loss & gastric adenocarcinoma: systematic review.
Presenting Author: Francisco Aguiar, São Paulo, Brazil

​

P03.13
Findings from the surveillance upper endoscopies in patients with gastric mucosal dysplasia at the baseline
Presenting Author: Laura Rotberga, Riga, Latvia

​

P03.14
Changes in lipid peroxidation and antioxidant protection in chronic atrophic gastritis and gastric cancer associated with Helicobacter pylori infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

​

P03.15
Evaluation of the glutathione part of antioxidant protection in the development of atrophy in chronic gastritis and gastric cancer associated with Helicobacter pylori infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

​

P03.16
Polyphenols Intake and Gastric Cancer: A quick review that precedes a case-control study in the Amazon region of Brazil
Presenting Author: Marcela Fagundes, São Paulo, Brazil

​

​

Electronic Poster Round 4: Helicobacter infection - pathogenesis and host response

P04.01
Helicobacter pylori upregulate epithelial cortactin expression in a CagA- and JNK-dependent manner
Presenting Author: Steffen Backert, Erlangen, Germany

​

P04.02
Helicobacter pylori PqqE protease cleaves junctional adhesion molecule A to disrupt tight junction functions
Presenting Author: Ceu Figueiredo, Porto, Portugal

​

P04.03
Effect of Helicobacter pylori eradication on the recurrence of gastric cancer after endoscopic submucosal dissection
Presenting Author: Jong-Jae Park, Seoul, Korea, Republic of

​

P04.04
Comprehensive integration of genome-wide association and gene expression studies reveals novel gene signatures for Helicobacter-induced gastric disease and potential therapeutic targets
Presenting Author: Mohamed Tarek Badr, Freiburg, Germany

​

P04.05
Inhibition of Polycomb Repressive Complex 2 expression and function by Helicobacter pylori.
Presenting Author: Rebecca FitzGerald, Dublin, Ireland

​

P04.06
Helicobacter pylori infection provides proangiogenic conditions in an experimental model of vascular endothelial cells
Presenting Author: Paulina Rusek-Wala, Lodz, Poland

​

P04.07
Helicobacter pylori infection, distribution of dupA virulence gene and associated clinical outcomes: the situation in Central West Brazil.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

​

P04.08
Expression of apoptosis and proliferation proteins by the cells of inflammatory infiltrate of gastric lamina propria in patients with peptic ulcer disease
Presenting Author: Vladislav Tsukanov, Krasnoyarsk, Russian Federation

​

P04.09
Revisited role of Helicobacter pylori cagPAI, CagA, VacA and GGT in apoptosis during infection of gastric epithelial cells
Presenting Author: Steffen Backert, Erlangen, Germany

​

P04.10
Local cytokine status in Helicobacter pylori infection
Presenting Author: Guzel Isaeva, Kazan, Russian Federation

​

P04.11
Analysis of the Helicobacter pylori vacA virulence gene in dyspeptic patients
Presenting Author: Mônica Barbosa, Goiânia, Brazil

​

P04.12
Searching for cross-reacting antibodies produced during Helicobacter pylori infection in an experimental animal model
Presenting Author: Agata Tomaszewska, Lodz, Poland

​

P04.13
Downregulation of pro-regenerative activity of IL-33 in the milieu of H. pylori lipopolysaccharide
Presenting Author: Weronika Gonciarz, Lodz, Poland

​

P04.14
ADP-heptose is the determinant of Helicobacter pylori responsible for the dampening of HLA-II expression in macrophages
Presenting Author: Marina de Bernard, Padova, Italy

​

P04.15
Pro-inflammatory and anti-inflammatory cytokines and immunoglobulins in the development of chronic atrophic gastritis with Helicobacter pylori infection
Presenting Author: Olga Smirnova, Krasnoyarsk, Russian Federation

​

P04.16
TLR1-SNP-rs4833095-genotype is not associated with inflammation phenotype in H.pylori-negative patients
Presenting Author: Alexander Link, Magdeburg, Germany

​

P04.17
Analysis of indicators characterizing the system immune response in patients with Helicobacter pylori
Presenting Author: Elizaveta Ageeva, Simferopol, Russian Federation

​

P04.18
Association between the Helicobacter pylori cagA virulence gene and the severity of gastroduodenal lesions
Presenting Author: Mônica Barbosa, Goiânia, Brazil

Electronic Poster Round 5: Epidemiology

​

P05.01
Relationship of alcohol and tobacco consumption and the development of gastric adenocarcinoma
Presenting Author: Mônica Barbosa, Goiânia, Brazil

​

P05.02
Detection of Helicobacter suis in pork meat products aimed to human consumption
Presenting Author: Miguel García-Ferrús, Valencia, Spain

​

P05.03
Evaluation of the chemioprotective role of pequi fruit (Caryocar brasiliense) in gastric cancer.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

​

P05.04
Prevalence of Helicobacter pylori infection in asymptomatic children from Southeastern Brazil
Presenting Author: Ana Carlos, Botucatu, Brazil

​

P05.05
Dietary patterns and Helicobacter pylori infection in dyspeptic patients in Central West Brazil.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

​

P05.06
Differences in management of Helicobacter pylori infection: an observational study
Presenting Author: Ruffin Ntounda, bruxelles, Belgium

​

P05.07
Helicobacter pylori is associated with uninvestigated dyspepsia in inhabitants of the Eastern Siberia administrative center
Presenting Author: Vladislav Tsukanov, Krasnoyarsk, Russian Federation

​

P05.08
Relationship between food habits and the development of gastric adenocarcinoma.
Presenting Author: Mônica Barbosa, Goiânia, Brazil

​

P05.09
Gastric cancer early mortality: a brazilian cohort study
Presenting Author: Tatiane Tiengo, São Paulo, Brazil

​

P05.10
Prevalence of Helicobacter pylori cagA, vacA, oipA and iceA genotypes in Russian patients with gastroduodenal diseases
Presenting Author: Alena Svarval, Saint Petersburg, Russian Federation

​

Electronic Poster Round 6: Microbiology and genomics of Helicobacter

​

P06.01
Phenotypic, Molecular, and Whole Genome Characterization of Antibiotic Resistance in Enterohepatic Helicobacter species
Presenting Author: Anthony Mannion, Cambridge, United States

​

P06.02
Detection & genotyping of H. pylori in environmental samples
Presenting Author: Irene Hortelano Martin, Valencia, Spain

​

P06.03
Genetic diversity of Helicobacter pylori strains isolated from single patients using Multilocus Sequence Typing (MLST)
Presenting Author: Parastoo Saniee, Tehran, Iran, Islamic Republic of

​

P06.04
Potential role of single nucleotide polymorphism of gluP and cgt genes in H. pylori biofilm Formation
Presenting Author: Kartika Fauzia, Yufu, Oita, Japan

​

P06.05
Peptidoglycan as a marker for isolation of endosymbiotic Helicobacter pylori and Staphylococcus from yeast
Presenting Author: Samira Heydari, Tehran, Iran, Islamic Republic of

​

P06.06
Prophage elements in Greek Helicobacter pylori clinical isolates
Presenting Author: Beatriz Martinez-Gonzalez, Athens, Greece

​

P06.07
Helicobacter pylori ‘s type 4 secretion systems as a gastroduodenal diseases marker
Presenting Author: Bui Hoang Phuc, Yufu, Japan

​

P06.08
Comparative genomic analysis in Colombian Helicobacter pylori isolates: a focus to virulence, antibiotic resistance, and population structure.
Presenting Author: Johanna Stepanian-Rozo, Bogotá, Colombia

​

P06.09
Genetic diversity of vacA variable i , d and c regions in Helicobacter pylori isolates from individual hosts
Presenting Author: Parastoo Saniee, Tehran, Iran, Islamic Republic of

​

​

Electronic Poster Round 7: Helicobacter and extragastroduodenal disease

​

P07.01
Mucus-degrading microbiota and proinflammatory T-cell responses underlie Helicobacter pylori induced colon carcinogenesis
Presenting Author: Anna Ralser, Munich, Germany

​

P07.02
Exploring the binding mechanisms of Helicobacter pylori to colon epithelial cells and induced downstream signaling
Presenting Author: Anna Ralser, Munich, Germany

​

P07.03
Circulating ghrelin decrease following Helicobacter pylori eradication
Presenting Author: Paula Mantero, Buenos Aires, Argentina

​

P07.04
Autoimmune disease did not result in a higher incidence of pernicious anemia among a cohort of 94 patients with active H. pylori infection presenting to a rheumatology clinic
Presenting Author: Michael Lovy, Palm Springs, United States

​

P07.05
Helicobacter pylori infection, monoclonal gammopathy of uncertain significance, and autoimmune disease in a cohort of 150 patients with pernicious anemia
Presenting Author: Michael Lovy, Palm Springs, United States

​

P07.06
Screening and diagnosis of Helicobacter pylori infection and autoimmune gastritis in patients with inflammatory bowel diseases
Presenting Author: Mila Kovacheva-Slavova, Sofia, Bulgaria

​

P07.07
Prevalence & impact of Helicobacter pylori in patients with cirrhosis
Presenting Author: Nouha Trad, Ariana, Tunisia

​

P07.08
The frequency of Helicobacter pylori and the structure of the gastric mucosa in elderly patients with esophagitis
Presenting Author: Vladislav Tsukanov, Krasnoyarsk, Russian Federation

​

P07.09
Comorbidity profile according to Helicobacter pylori infection status
Presenting Author: Mônica Barbosa, Goiânia, Brazil

EP08 Electronic Poster Round 8: Paediatric conditions

​

P08.01
Faecal microbiota in infants and toddlers with allergy
Presenting Author: Erika Luse Ilva Daugule, Riga, Latvia

​

P08.02
Cytokine profile in schoolchildren with Helicobacter pylori with familial burden of stomach cancer
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

​

P08.03
Cytokine levels in Helicobacter pylori associated gastritis in children with familial burden of peptic ulcer disease
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

​

P08.04
The course of Helicobacter pylori associated gastritis in schoolchildren of Buryatia
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

​

P08.05
CK20 in gastric mucosa in children with Helicobacter pylori-associated gastritis with superimposed GERD
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

​

P08.06
Expression of CK20 in the stomach in children with Helicobacter pylori and familial predisposition to peptic ulcer disease
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

​

P08.07
CK7 in schoolchildren with Helicobacter pylori-associated gastritis
Presenting Author: Tamara Polivanova, Krasnoyarsk, Russian Federation

​

Electronic Poster Round 9: Gut microbiota and non-intestinal disease

​

P09.01
Effects of indigenous fecal bacteria consortium treatment in patients with metabolic syndrome
Presenting Author: Konstantin Ermolenko, Saint-Petersburg, Russian Federation

EP10 Electronic Poster Round 10: Microbiota and intestinal disease

​

P10.01
Double blind RCT study on the efficacy of L. reuteri 4659 in reducing inflammatory markers in patients affected by acute uncomplicated diverticulitis
Presenting Author: Veronica Ojetti, Rome, Italy

​

P10.02
Effects of cytokines in chronic gastroduoenitis associated with Helicobacter pylori, fungi and protozoa invasion
Presenting Author: Elena Agafonova, Kazan, Russian Federation

​

P10.03
Rifaximin for small intestinal bacterial overgrowth: a retrospective study
Presenting Author: Carolina Mosoni, Rome, Italy

​

P10.04
Gut microbiota modification in patients with inflammatory bowel diseases who do not received and received biological therapy
Presenting Author: Natalia Baryshnikova, St-Petersburg, Russian Federation

​

Electronic Poster Round 11: Microbiota and cancer

​

P11.01
Presence of colibactin-producing E.coli in biliary juice and development of cholangiocarcinoma
Presenting Author: Parastoo Saniee, Tehran, Iran, Islamic Republic of

​

P11.02
Bacteria-derived extracellular vesicles in urine as a novel biomarker for gastric cancer: integration of liquid biopsy and metagenome analysis
Presenting Author: Jae Gyu Kim, Seoul, Korea, Republic of

​

Electronic Poster Round 12: Gut microbiota manipulation

​

P12.01
Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during the Helicobacter pylori eradication therapy
Presenting Author: Sara Cifuentes, Quito, Ecuador

​

P12.02
Original article. Fecal microbiome transplantation for recurrent CDI treatment: efficacy, short and long-term follow-up results from consecutive case series.
Presenting Author: Tadas Urbonas, Kaunas, Lithuania

​

Electronic Poster Round 13: Microbiota detection and analyses

​

P13.01
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol associated liver disease
Presenting Author: Dionisi Tommaso, Rome, Italy

​

P13.02
Gut bacteria functionality profiles and diversity index detected by the GA-map® Dysbiosis Test Lx
Presenting Author: Kristin Gravdal, Oslo, Norway

​

P13.03
Effects of green tea and post-fermented green tea extract on obese adults: a randomized double-blind, placebo-controlled trial focused on change of gut microbiota
Presenting Author: MUNJIN JU, Seongnam, Gyeonggi, Korea, Republic of

​

P13.04
A portable H2-breath tracker: laboratory assessment.
Presenting Author: Elena Kolomina, St. Petersburg, Russian Federation

​